Elephas Biosciences

Executive Summary

Elephas Biosciences, a Madison, Wisconsin-based diagnostics company founded in 2018, has developed the elive™ platform, a first-in-class functional assay that uses live tumor biopsies to predict patient response to immunotherapies. By directly measuring the functional interaction between a patient's tumor and immune cells, elive™ aims to de-risk drug development for pharmaceutical partners and guide oncologists in selecting the most effective immunotherapy for each patient. The platform addresses a critical unmet need in oncology, as current biomarkers often fail to accurately predict responses to immunotherapies, leading to high trial failure rates and suboptimal treatment choices. Elephas has the potential to become a key enabling technology for precision immunotherapy, partnering with biopharma to streamline clinical development and with clinics to improve patient outcomes. As a private company, Elephas is well-positioned to capture a significant share of the growing functional diagnostics market, which is projected to expand as immunotherapy adoption increases.

Upcoming Catalysts (preview)

• Q3 2026Pharma partnership for drug development60% success
• Q4 2026Publication of clinical validation data70% success
• Q2 2026Series B funding round80% success